Products
Contact Us
CanAg Diagnostics (Beijing) Co., Ltd.
Room 1151, Hotel Nikko New Century Beijing Office Tower Building,
No.6 Southern Road Capital Gym, Haidian District, Beijing, China
Post code: 100044
Tel: +86 10 8528 8156 68492672
Fax: +86 10 8528 8382
E-mail :canag@canag.com.cn
Mobile Phone：17896035653
logistics Department
Tel: +86 10 88431258/2778/2621
Fax: +86 10 88434018
E-mail：order@canag.com.cn
PHOSPHO-TAU(181P)Home>Products>PHOSPHO-TAU(181P)
The INNOTEST PHOSPHO-TAU(181P) is a solid-phase enzyme immunoassay for the quantitative determination of phosphorylated Tau (Phospho-Tau(181P)) in human cerebrospinal fluid (CSF). In Alzheimer disease (AD) pathology, the phosphorylation of tau protein is disturbed, leading to hyperphosphorylation and the emergence of new sites of phosphorylation. This assay measures specifically the phosphorylation in position 181 threonine.
The combined use of CSF- β -amyloid(1-42) and CSF-Tau marker concentrations allows differentiation between AD and normal aging or other neurological diseases such as depression. As AD diagnosis marker, the results obtained with this assay should be interpreted in combination with other clinical and diagnostic information (e.g. using results obtained with the INNOTEST hTAU Ag and the INNOTEST β -AMYLOID). The discrimination of AD from non-AD types of dementia such as dementia with Lewy Bodies may be further improved using the quantification of CSF-phospho-Tau(181) .
The combined use of CSF- β -amyloid(1-42) and CSF-Tau marker concentrations allows differentiation between AD and normal aging or other neurological diseases such as depression. As AD diagnosis marker, the results obtained with this assay should be interpreted in combination with other clinical and diagnostic information (e.g. using results obtained with the INNOTEST hTAU Ag and the INNOTEST β -AMYLOID). The discrimination of AD from non-AD types of dementia such as dementia with Lewy Bodies may be further improved using the quantification of CSF-phospho-Tau(181) .
